June personnel changes in the pharmaceutical industry: 21 executives leave 11 executives to new positions.

TextTen yuanin June 2020, the pharmaceutical listed companies issued 32 executive personnel changes, involving Fosun Pharma, China Pharmaceuticals, China Resources Shuanghe, Fuan Pharmaceuticals, Nocheng Jianhua and other 22 biopharmaceutical companies, according to incomplete statistics, a total of 21 executives from 18 biopharmaceutical companies applied for separation and were approved in June, including 15 men and six womenThe trend at the top of pharmaceutical companies has slowed compared with the departures of 29 executives from 21 companies last monththe change of executive departure in June 2020,
it is worth mentioning that four of the executives who left in June were paid more than 1 million in 2019,1) MrFan Yanxi, director of China Resources Shuanghe, submitted a written resignation report on June 3, 2020, saying that due to the work arrangement, the company applied to resign from the 8th Board of Directors, a member of the Special CommitteeAccording to the information, Fan Yanxi has served as secretary of the company's board of directors since June 22, 2018 and as a director of the company from January 4, 2019, with the original term ending on June 21, 2021, and his pre-tax remuneration from the company in 2019 totaled $2,039.6 millionit is understood that Fan Yanxi was the deputy head of finance, deputy head of the accounting and accounting department, deputy director of the finance department, director, deputy accountant, discipline committee member, chief accountant of the finance department of China Textile Machinery (Group) Co., Ltd., deputy director of finance, deputy director of finance department of China Huayuan Life Industry Co., Ltd., chief accountant of Beijing Pharmaceutical Group Co., Ltd., manager of finance department, Beijing Wandong Medical Equipment Co., Ltd2) MrLi Jianqing, Vice President of Fosun Pharma, submitted a written resignation report to the Company on June 1, 2020, saying that he had resigned as Vice President for personal reasonsAccording to Fosun Pharma's 2019 financial results, Li Jianqing joined the company in November 2013 and has served as vice president of the company since January 21, 2020, with the original term ending on June 24, 2022In addition, Li Jianqing owns 23,450 shares of the company and received a total pre-tax compensation of RMB1.8989 million from the Company in 20193) MrGao Lei, Deputy General Manager of HaPharmaceutical Co., Ltd., submitted a written resignation report to the company on June 10, 2020, stating that he had resigned as Deputy General Manager of the Company for personal reasons and would not hold any other position son in the company after his resignation Gao Lei received a total of 1.4 million yuan in pre-tax compensation from the company in 2019, according to the 2019 financial results, and his original term as deputy general manager of the company was dated October 25, 2020 before joining HaPharmaceutical, He was a senior strategic consultant for Navigant Consulting Medical Medicine, a Consulting Firm, a senior manager of The U.S Investment Bank of Ernst and Young, a general manager of the overseas investment division of Tianshi Pharmaceutical Group AG, and a managing director of Tianshili Capital 4) Mr Qi Tie-ho, Chairman of Lisheng Pharmaceuticals, submitted a written resignation report to the Company on June 11, 2020, stating that he would no longer serve as a director, chairman of the board of directors and a member of the Strategy and Development Committee due to changes in his work The total pre-tax compensation it received from the company in 2019 was $1.07 million After the departure of the company's senior management, the rapid replacement of suitable candidates to supplement the company's administrative structure of the vacancy, the company's stable operation of the urgent task According to incomplete statistics, in June this year, a total of six senior executives were hired to join the new company after leaving their posts, three executives were appointed to new positions within the group, and three industry figures were invited to join the new company and hold directorships the June 2020 executive position information table of pharmaceutical listed companies
it is worth mentioning that pharmaceutical Mingkang, Deqi Pharmaceuticals and Novartis Jianhua have hired three prominent people from Xinji, Sanofi and BFAM Partners to serve as senior executives of the company, enriching the company's organizational structure They are: Mr zhang Youxiang, former vice president of New Base Company and head of global cell therapy production, joined the company on June 1, 2020 as CEO of the company's high-end treatment division The High-End Therapeutics Division is the Pharmaceutical Mingkang Contract Research and Development Production Organization (CDMO) focused on cell and gene therapy, and Dr Zhang will be responsible for the strategic planning, technology development and operational management of the business platform worldwide it is understood that Zhang yuxiang previously served as vice president of new-based pharmaceutical stake and head of global cell therapy production under Baxter," responsible for overseeing the CAR-T drug production network, leading the scientific and technical team for global production, and also served in Switzerland as global head of Roche Pharmaceutical Engineering and Strategy, vice president of Roche's Shanghai technology department and other senior management positions, as well as senior director of gene tektronical global production science and technology department, BASF Mr Long Zhenguo, a former fund manager of BFAM Partners, joined Deqi Pharma as Chief Financial Officer (CFO) on June 8, 2020, responsible for the company's financial strategy development, risk management, financial reporting and investment matters to drive the company's long-term growth in the biopharmaceutical industry At the same time, he will support and lead the company's business development and mergers and acquisitions, business operations and other work Mr , formerhead of Sanofi's Core Products Division, joined Novartis on June 28, 2020 as Chief Commercial Officer (CCO) to lead the sales, marketing, access and dealer management team to implement the company's commercialization strategy it is understood that Jin Xiaodong in the global medical and health field for nearly 25 years, before joining Novo Cheng Jianhua, served as the sanofi core product stilt head Under its leadership, Sanofi China has further consolidated its position as a leader in the prevention and treatment of cardiovascular chronic diseases, and its business segment will break through annual sales of 1 billion euros in 2018 Prior to that, he also served as General Manager of Abbott Diabetes Division and General Manager of Greater China, and served Novartis for more than 13 years, serving as Sales Manager, Regional Sales Director, Marketing Director and Head of Chengdu Branch .